$0.60
(Market cap
$190 Mln
Recently Viewed
Clear AllMarket cap
$190 Mln
Revenue (TTM)
$103 Mln
P/E Ratio
--
P/B Ratio
32.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
21.8
Debt to Equity
8.1
Book Value
$0.7
EPS
$-4.2
Face value
--
Shares outstanding
9,167,040
CFO
$-22.16 Mln
EBITDA
$-32.14 Mln
Net Profit
$-31.32 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sanara Medtech Inc (SMTI)
| -11.0 | 5.8 | -9.1 | -27.6 | -24.6 | -7.2 | 10.9 |
|
BSE Sensex*
| -6.9 | 6.3 | -5.3 | 0.4 | 9.8 | 10.5 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sanara Medtech Inc (SMTI)
| -29.7 | -19.1 | -9.7 | 54.0 | -40.8 | 209.9 | 393.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sanara Medtech Inc (SMTI)
|
20.8 | 190.4 | 103.1 | -37.6 | 8.9 | -165.7 | -- | 32.4 |
| 13.9 | 4,437.3 | 3,018.8 | 72.1 | 12.6 | -80 | 63.2 | 105.4 | |
| 40.9 | 5,228.7 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.2 | 14.1 | |
| 189.0 | 9,667.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 109.5 | |
| 76.8 | 14,879.0 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 46.2 | 4,910.2 | 761.4 | 99.7 | 7.3 | 15 | 56.3 | 7.6 | |
| 13.3 | 10,903.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 17.9 | 2.7 | |
| 23.7 | 11,550.7 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.8 | 7,186.6 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.5 | 1.0 | |
| 231.8 | 4,622.8 | 268.1 | 124.5 | 60.0 | 13.5 | 37.8 | 4.4 |
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical... hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. Read more
Executive Chairman
Mr. Ronald T. Nixon
Executive Chairman
Mr. Ronald T. Nixon
Headquarters
Fort Worth, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Sanara Medtech Inc (SMTI) is $20.38 (NASDAQ) as of 17-Apr-2026 16:00 EDT. Sanara Medtech Inc (SMTI) has given a return of -24.56% in the last 3 years.
Since, TTM earnings of Sanara Medtech Inc (SMTI) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.59
|
35.44
|
|
2024
|
-27.48
|
6.74
|
|
2023
|
-76.41
|
7.33
|
|
2022
|
-45.86
|
8.70
|
|
2021
|
-26.11
|
6.75
|
The 52-week high and low of Sanara Medtech Inc (SMTI) are Rs 35.95 and Rs 16.05 as of 20-Apr-2026.
Sanara Medtech Inc (SMTI) has a market capitalisation of $ 190 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sanara Medtech Inc (SMTI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.